- Stock: In Stock
- Brand: NIPRO JMI Pharma Ltd.
- Product ID: Empagliflozin + Metformin Hydrochloride
100% Secure Payment
Empa Met 5 mg+500 mg Tablet, 1 Box
Description:
Empagliflozin is an inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2). SGLT2 is the predominant transporter, responsible for reabsorption of glucose from the kidney back into the circulation. By inhibiting SGLT2, Empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose and thereby increases urinary glucose excretion.
Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug, used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. It does not produce hypoglycemia. Metformin Hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.
Indication
Dosage & Administration
Recommended individualized starting dose:
In patients on Metformin Hydrochloride, switch to EmpaMet containing Empagliflozin 5 mg with a similar total daily dose of Metformin Hydrochloride. In patients on Empagliflozin, switch to EmpaMet containing Metformin Hydrochloride 500 mg with a similar total daily dose of Empagliflozin. In patients already treated with Empagliflozin and Metformin Hydrochloride separately switch to EmpaMet containing the same total daily doses of each component.
In patients with volume depletion not previously treated with Empagliflozin, correct this condition before initiating EmpaMet.
Renal impaired patient: Assess renal function before initiating EmpaMet. In patients with an eGFR below 45 mL/min/1.73 m2 EmpaMet is contraindicated.
Contraindication
Precaution
Side Effects
Drug Interaction
Overdose
Pregnancy & Lactation
USE IN CHILDREN & ADOLESCENT:
Safety and effectiveness of EmpaMet in pediatric patients under 18 years of age have not been established.